With an in-line performance expected in Q3, ABT stock may trade sideways next week. However, we would watch out for its ...

a leader in performance nutrition products, was also acquired. In 2006, Abbott acquired Guidant, a leader in coronary and vascular products, and Kos Pharmaceuticals, a speciality pharma company ...

Abbott (NYSE: ABT) recently reported its Q3 results, with revenues and earnings slightly above our expectations.

Abbott and Reckitt's Mead Johnson will not be allowed to show jurors a statement by U.S. government agencies and a government ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...

Abbott Laboratories, a healthcare giant with diverse divisions, is normalizing post-pandemic as its medical devices drive ...

The CEO at the Illinois-based company with operations in Minnesota expects earning to return to a pre-pandemic profit model ...

Abbott Laboratories narrowed its full-year profit outlook, raising the midpoint slightly, as strong demand for its diabetes ...

Key Takeaways Abbott Laboratories beat third-quarter profit and sales estimates on strong demand for its medical ...

To help affected families and communities, Abbott and Abbott Fund are working with our longstanding disaster relief partner ...

ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna ...

Abbott Laboratories is a diversified healthcare company with strong segments, particularly Medical Devices. Read why I assign ...